48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
_256_384.png)
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Amarex Clinical Research guides its client to phase II of FDA trials
New Director supports NASDAQ rule on diversity
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
